興科蓉醫藥(06833.HK)公佈中期業績 收益大幅增加40.1% 少女針項目臨牀效果良好
格隆匯8月28日丨興科蓉醫藥(06833.HK)公吿,截至2024年6月30日止六個月,公司收益增加40.1%或人民幣436.8百萬元至人民幣1,526.9百萬元,其中藥品銷售收益增加約人民幣439.7百萬元。
報吿期內,純利增加約人民幣4.3百萬元至人民幣23.9百萬元。報吿期內,每股基本及攤薄盈利為人民幣1.17分(截至2023年6月30日止六個月:人民幣0.965分)。
儘管面臨匯率波動的挑戰,集團依然堅持高質量運營,保持對市場的敏鋭洞察力,並通過審慎的財務控制和多元化的戰略佈局應對市場變化。集團將繼續加強市場拓展,優化產品結構,提升客户滿意度,並積極實施有效措施來降低成本和風險。期待在未來的發展中,集團能夠取得更好的業績表現,實現穩健的增長。
醫美領域為集團未來發展的重要方向。於報吿期內,少女針項目臨牀試驗入組已超過50%,臨牀效果良好,預計2024年7月完成所有受試者入組,較預期提前1個月,臨牀試驗完成時間為2025年下半年。私密針項目已完成動物預試驗,數據分析中,持續推進。自主研發的新型材料及對應的三類醫療器械將應用於與少女針不同醫美用途皺紋的改善,目前已初步完成理論研究,小試研究結束待安全性評價。
公司表示,集團將繼續在醫藥健康行業中發揮領導作用,致力於提供高品質的醫療產品和服務。公司將以人為本,緊跟科技發展的步伐,不斷創新業務模式,提升產品質量,旨在為患者和醫療機構提供更加優質、安全、可靠的醫療解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.